// App-Quantinova.ai

TPS4156 : EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study.

Researchers

Presenter

  • Elizabeth Catherine Smyth

Principal Investigators

  • Ellen Peeters

  • Maren Kristina Knoedler

  • Anne Giraut

  • Anna Dorothea Wagner

  • Markus H. Moehler

  • Nicole C.T. van Grieken

  • Magnus Nilsson

  • Murielle E. Mauer

  • Florian Lordick

Medical Centers

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • EORTC HQ, Brussels, Belgium

  • University Cancer Center Leipzig, Leipzig, Germany

  • Lausanne University Hospital, Lausanne, Switzerland

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands

  • Division of Surgery, CLINTEC, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden

Locations

  • United Kingdom

  • Belgium

  • Germany

  • Switzerland

  • Netherlands

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

  • Controlled

Phase

  • II

Study Id's

  • NCT03443856

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved